Vitamin B6 Injection Research Articles

Cantharidin induces apoptosis of human triple negative breast cancer cells through mir-607-mediated downregulation of EGFR

BackgroundTriple negative breast cancer (TNBC) is a major subtype of breast cancer, with limited therapeutic drugs in clinical. Epidermal growth factor receptor (EGFR) is reported to be overexpressed in various TNBC cells. Cantharidin is an effective ingredient in many clinical traditional Chinese medicine preparations, such as Delisheng injection, Aidi injection, Disodium cantharidinate and vitamin B6 injection. Previous studies showed that cantharidin had satisfactory pharmacological activity on a variety of tumors. In this study, we aimed to study the therapeutic potential of cantharidin for TNBC treatment by targeting EGFR, and expound its novel regulator miR-607.MethodsThe effect of cantharidin on breast cancer in vivo was evaluated by 4T1 mice model. Then the effects of cantharidin on TNBC cells was assessed by the MTT, colony formation, and AnnexinV-PE/7AAD staining. Cantharidin acts on EGFR were verified using the cell membrane chromatography, RT-PCR, Western blotting, MTT, and so on. Mechanistic studies were explored by dual-luciferase report assay, RT-PCR, western blotting, and immunofluorescence staining assay.ResultsCantharidin inhibited TNBC cell growth and induce apoptosis by targeting EGFR. miR-607 was a novel EGFR regulator and exhibited suppressive functions on TNBC cell behaviors. Mechanistic study showed that cantharidin blocked the downstream PI3K/AKT/mTOR and ERK/MAPK signaling pathway.ConclusionOur results revealed that cantharidin may be served as a potential candidate for TNBC treatment by miR-607-mediated downregulation of EGFR.Graphical

Long-term outcomes of infantile spasms in children treated with ketogenic diet therapy in combination with anti-seizure medications in a resource-limited region.

Despite numerous guidelines, the overall outcome of infantile spasms is poor, with only a small number of patients being able to attend school. The purpose of this study was to investigate long-term outcomes. Patients had poor access to the recommended first-line anti-seizure medications (ASMs), such as hormones (corticotropin or prednisolone/prednisone) and vigabatrin, and their alternative treatment was other ASMs and a ketogenic diet. Patients suffering from infantile spasms who had at least 2 years of medical records in the electronic medical record system between January 2014 and August 2022 were included in this study. Patient information was retrospectively reviewed. All patients had received ketogenic diet therapy (mainly classical ketogenic diet therapy). The ketogenic diet therapy was combined with ASMs not used as first-line therapies. The primary endpoint outcome measure was the number of patients with seizure freedom. The secondary measures included the duration of ketogenic diet therapy, choice of ASMs, and patient development at the last visit. A total of 177 patients with infantile spasms were included, and 152 (86%) of them had seizure freedom. The median duration from the first to the last hospital visit was 53.27 months, and the number of visits was 47.00. The median age at the initial hospital visit was 8.00 months, and the median age at initiation of the ketogenic diet was 17.73 months. At the last visit, the proportions of patients with neurodevelopmental delay, developmental epileptic encephalopathy, drug-resistant epilepsy, and generalized seizures increased significantly. The frequently used ASMs were topiramate, valproic acid, levetiracetam, nitrazepam, and vitamin B6 injection, while the recommended first-line drugs corticotropin and vigabatrin were rarely selected. The study duration of 9.5 years was divided into three periods but the prescription of ASMs did not change significantly between these periods. Although the seizure freedom rate was high with ketogenic diet therapy combined with non-standard ASMs, the patients had a significant neurodevelopmental delay at the last visit, which was, however, similar to that of standard treatment. To improve the outcomes of infantile spasms, multicenter clinical trials of the ketogenic diet as a first-line treatment in combination with non-standard ASMs are needed.

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.

Background: Given the limitations of Western medicine (WM) for the treatment of non-small cell lung cancer (NSCLC) and the wide exploration of Chinese herbal injections (CHIs), systematically evaluate the efficacy of Various CHIs Combined with WM for Non-small Cell Lung Cancer. In this study, we performed a network meta-analysis to evaluate the comparative efficacy of 16 CHIs combined with WM regimens for the treatment of NSCLC. Methods: Literature databases were searched from their inception to November 2021, and all randomized control trials (RCTs) involving NSCLC patients treated with a combination of Chinese and WM were retrieved. Outcomes, including disease control rate, survival quality score, incidence of gastrointestinal adverse reactions, incidence of leukopenia, and incidence of thrombocytopenia, were analyzed using RevMan (5.3), Stata17, and R software. Surface under the cumulative ranking curve (SUCRA) probability values were calculated to rank the treatments examined, and clustering analysis was used to compare the effects of CHIs on different outcomes. Results: A total of 389 studies involving 31,263 patients and 16 CHIs were included. The 16 CHIs were: Aidi injection (ADI), Huachansu injection (HCSI), oil of Ophiopogon injection (OOMI), disodium cantharidinate and vitamin B6 injection (DCI), Shenfu injection (SFI), Shenmai injection (SMI), Shenqi Fuzheng injection (SQFZI), Chansu injection (CSI), Delisheng injection (DLSI), Fufang Kushen injection (FFKSI), Huangqi injection (HQI), Kangai injection (KAI), Kanglaite injection (KLTI), Shengmai injection (SI), Xiangguduotang injection (XGDTI), and Xiaoaiping injection (XAPI). The results of the network meta-analysis showed that, with WM treatment as a co-intervention, CSI was most likely to improve the disease control rate (SUCRA = 80.90%), HQI had the highest probability of being the best option for improving the survival quality score (SUCRA = 82.60%), DCI had the highest probability of reducing the incidence of gastrointestinal adverse reactions (SUCRA = 85.50%), HCSI + WM had the highest probability of reducing the incidence of thrombocytopenia (SUCRA = 91.30%), while SMI had the highest probability of reducing the incidence of leukopenia (SUCRA = 79.10%). Conclusion: CHIs combined with WM is proved to be more effective than WM alone, which may be beneficial to NSCLC patients. SMI + WM and DCI + WM are most likely the optimal CHI to improve disease control rates, survival quality score, and reduce adverse effects. This study has limitations; therefore, higher quality RCTs and real-world evidence are required to support our conclusions.

Carpal Tunnel Syndrome in Primary Care Settings: What We Should Know

Carpal tunnel syndrome (CTS) remains one of the most common peripheral nerve entrapment syndromes. The patient may experience pain, numbness, and tingling in hand and arm of the affected individual. Treatment for CTS falls under two choices between conservative and surgical therapy. Mild and moderate symptoms are offered to be treated with conservative treatments, including oral and transvenous steroids, vitamin B6, vitamin B12, and corticosteroids injection. A further option is using a surgical procedure with a carpal tunnel release (CTR) by cutting the transverse carpal ligament (TCL) to increase space and relieve the pressure within the tunnel. As there are many cases of CTS worldwide, astute primary care physicians (PCP) must diagnose and choose the right treatment option. Clinicians should acknowledge some basic information about CTS to provide cost-effective and proper treatment. Clinicians can select Conservative treatments before referring the patient to an orthopedic surgeon or neurosurgeon. Failure to respond to conservative therapies is a case that needs hospital referral consideration. Keywords: carpal tunnel syndrome, primary care, primary care physician

Comparison of surgical out come between virgin carpal tunnel syndrome and previous local steroid injected tunnel

Carpal tunnel syndrome(CTS) is the most commonly occurring peripheral nerve compression neuropathy and its condition characterized by an abnormality of the median nerve function due to compression of the nerve within the carpal tunnel. Surgical release of the transverse carpal ligament is an effective treatment for patients with CTS. Non-steroidal anti-inflammatory drugs, diuretics, vitamin B6 injection, ultrasound therapy, laser therapy, acupuncture, magnetic therapy, bracing and local steroid injections have been used for closed treatment of CTS and effective results in the short-term treatment have been demonstrated clearly only for bracing and local steroid injections. Aim: was to identify the effect of local steroid injection on the outcome of surgical release of CTS. A prospective study that was conducted in the Orthopedic Department of at Basra General Hospital during the period from 1st of July 2005 till end of September 2006 on 40 patients, 20 of them with received local steroid injection (group A) and 20 without local steroid injection (group B virgin carpal tunnel) operations done to release the tunnel with monthly follow up by telephone call because of social and security problems at time of study. Pearson’s Chi–square test was used to assess statistical association between injection of local steroid and outcome of CTS surgery. A level of P – value less than 0.05 was considered significant. Postoperatively, in Group A, night pain and grip power were found to be improved in 17 (85%) and 11 (55%) of women, respectively, while 16 (80%) relieved from night pain, paresthesia and numbness. On the other hand, the postoperative follow up of women in group B showed that the improvement of night pain was occurred in 20 cases (90%), relieving of night pain, paresthesia and numbness in 17 (85%), and improvement of grip power was reported in 12 (60%). The analysis of association didn’t show statistical significant difference (P > 0.05) in surgical outcome between study groups. In conclusion; local steroid injection for CTS prior to surgery didn’t affect outcome of surgical release.

Comparison of surgical out come between virgin carpal tunnel syndrome and previous local steroid injected tunnel

"Carpal tunnel syndrome(CTS) is the most commonly occurring peripheral nerve compression neuropathy and its condition characterized by an abnormality of the median nerve function due to compression of the nerve within the carpal tunnel. Surgical release of the transverse carpal ligament is an effective treatment for patients with CTS. Non-steroidal anti-inflammatory drugs, diuretics, vitamin B6 injection, ultrasound therapy, laser therapy, acupuncture, magnetic therapy, bracing and local steroid injections have been used for closed treatment of CTS and effective results in the short-term treatment have been demonstrated clearly only for bracing and local steroid injections. Aim: was to identify the effect of local steroid injection on the outcome of surgical release of CTS. A prospective study that was conducted in the Orthopedic Department of at Basra General Hospital during the period from 1st of July 2005 till end of September 2006 on 40 patients, 20 of them with received local steroid injection (group A) and 20 without local steroid injection (group B virgin carpal tunnel) operations done to release the tunnel with monthly follow up by telephone call because of social and security problems at time of study. Pearson’s Chi–square test was used to assess statistical association between injection of local steroid and outcome of CTS surgery. A level of P – value less than 0.05 was considered significant. Postoperatively, in Group A, night pain and grip power were found to be improved in 17 (85%) and 11 (55%) of women, respectively, while 16 (80%) relieved from night pain, paresthesia and numbness. On the other hand, the postoperative follow up of women in group B showed that the improvement of night pain was occurred in 20 cases (90%), relieving of night pain, paresthesia and numbness in 17 (85%), and improvement of grip power was reported in 12 (60%). The analysis of association didn’t show statistical significant difference (P > 0.05) in surgical outcome between study groups. In conclusion; local steroid injection for CTS prior to surgery didn’t affect outcome of surgical release."

Disodium Cantharidinate and Vitamin B6 Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.

Purpose Disodium cantharidinate and vitamin B6 (DCVB6) injection is effective and widely used for the clinical treatment of non-small-cell lung cancer (NSCLC). This meta-analysis aimed to provide evidence-based medical data for clinical treatment with DCVB6 injection. Methods We searched 7 medical databases up to January 2018 for all randomized controlled trials (RCTs) based on DCVB6 injection combined with chemotherapy in patients with NSCLC. A manual search in relevant journals and of relevant literature on other websites was also performed. Data extraction and quality assessment were conducted independently by two reviewers. Subsequently, a meta-analysis was conducted using RevMan 5.3 software. Pooled risk ratio (RR) with 95% confidence interval (CI) was used to evaluate dichotomous and continuous outcomes, respectively. The PROSPERO ID was CRD42018086377. Results A total of 19 RCTs were included. The results of the meta-analysis indicated that the DCVB6 injection combined with chemotherapy was superior to chemotherapy alone regarding objective response rate (RR=1.58, 95% CI 1.40-1.79), Karnofsky performance score (RR=1.68, 95% CI 1.42-1.99), clinical symptom (RR=1.68, 95% CI 1.44-1.96), white blood cell toxicity (RR=0.36, 95% CI 0.27-0.49), platelet toxicity (RR=0.46, 95% CI 0.33-0.63), and vomiting (RR=0.50, 95% CI 0.37-0.67). Conclusions The current evidence suggests that DCVB6 injection combined with chemotherapy could increase objective response rate and Karnofsky performance score, improve clinical symptoms, and reduce side effects caused by chemotherapy in patients with NSCLC. However, these results should be carefully interpreted due to the low-quality methodology and the small sample sizes of the trials, and our conclusions should be verified by high-quality, large-scale, double-blinded RCTs.

Clinical analysis of non-specific immunotherapy in patients with hepatocellular carcinoma after radiofrequency ablation

Objective To study the curative efficacy of non-specific immunotherapy in patients with hepatocellular carcinoma after radiofrequency ablation. Methods The clinical data of 120 patients with hepatocellular carcinoma in our hospital from December 2012 to December 2014 were retrospectively analyzed. According to the different methods of treatment after the operation, they were divided into the observation group (n=60) and the control group (n=60). All the patients underwent elective operation of radiofrequency ablation, and the control group was treated with routine treatment after operation, while the observation group was treated with non-specific immunotherapy (recombinant human interleukin-2 injection+ thymalfasin+ disodium cantharidinate and vitamin B6 injection). After 3 weeks of treatment, the changes of cellular immune function, humoral immune function and quality of life were compared between the two groups before and after treatment, and the clinical efficacy and 1-, 2- and 3-year survival rates were compared. Results After treatment, in the cellular immune function, the CD3+ [(62.31±9.65)% vs. (57.08±8.03)%], CD8+ [(26.85±3.22)% vs. (33.41±3.86)%], CD4+ /CD8+ (1.95±0.34 vs. 1.53±0.27) and natural killer cells [(25.76±4.53)% vs. (21.14±4.20)%] of the observation group were better than those of the control group, and the differences were statistically significant (t=3.227, P<0.001; t=10.109, P<0.001; t=7.493, P<0.001; t=5.793, P<0.001). In the humoral immune function, the IgG [(19.45±2.45) g/L vs. (15.93±2.07) g/L], IgM [(2.15±0.42) g/L vs. (1.83±0.31) g/L], IgA [(3.08±0.79) g/L vs. (2.73±0.56) g/L] of the observation group were better than those of the control group, and the differences were statistically significant (t=8.501, P<0.001; t=4.748, P<0.001; t=2.800, P<0.001). In the quality of life scale, the social function score (59.73±4.62 vs. 53.91±3.84), physical function score (55.83±5.62 vs. 47.85±5.17), role function score (51.64±5.83 vs. 46.82±5.46), cognitive function score (64.82±5.19 vs. 58.04±4.92) and emotional function score (68.94±5.62 vs. 60.38±5.10) of the observation group were significantly higher than those of the control group, and the differences were statistically significant (t=7.504, P<0.001; t=8.095, P<0.001; t=4.674, P<0.001; t=7.344, P<0.001; t=8.737, P<0.001). The clinical efficacy of the observation group was significantly higher than that of the control group (81.67% vs. 65.00%), and the difference was statistically significant (χ2=4.261, P=0.039). The 1-year survival rate (91.67% vs. 78.33%), 2-year survival rate (85.00% vs. 68.33%) and 3-year survival rate (75.00% vs. 53.33%) of the observation group were significantly higher than those of the control group, and the difference was statistically significant (χ2=4.781, P=0.029). Conclusion Non-specific immunotherapy for patients with hepatocellular carcinoma after radiofrequency ablation can effectively improve immune function, and it is helpful to improve clinical efficacy and quality of life. Key words: Carcinoma, hepatocellular; Catheter ablation; Non-specific immunotherapy; Immune function

Efficacy and safety of sodium cantharidinate and vitamin B6 injection for the treatment of digestive system neoplasms: a meta-analysis of randomized controlled trials.

ObjectiveTo systematically evaluate the efficacy and safety of sodium cantharidinate and vitamin B6 (SC/B6) combined with conventional medical treatment (CMT) for the treatment of patients with advanced digestive system neoplasms (DSNs).MethodsThe Cochrane Library, Embase, PubMed, Web of Science, Chinese Scientific Journal Database (VIP), China National Knowledge Infrastructure, and Wanfang databases were searched for clinical trials using SC/B6 for DSNs. Outcome measures, including therapeutic efficacy, quality of life (QoL), and adverse events, were extracted and systematically evaluated.ResultsData from 24 trials including 1,825 advanced DSN patients were included. Compared with CMT alone, its combination with SC/B6 significantly improved the patients’ overall response rate (OR =2.25, 95% CI =1.83–2.76, P<0.00001), disease control rate (OR =2.41, 95% CI =1.85–3.15, P<0.00001), and QoL improvement rate (OR =2.75, 95% CI =2.13–3.55, P<0.00001). Moreover, adverse events caused by chemotherapy, including leukopenia, nausea and vomiting, gastrointestinal side effects, hepatotoxicity, diarrhea, transaminase disorder, myelosuppression, anorexia, and anemia, were significantly alleviated (P<0.05) when SC/B6 was applied to DSN patients. Nephrotoxicity, thrombocytopenia, hand-foot syndrome, and oral mucositis were not significantly alleviated in patients receiving combination therapy (P>0.05).ConclusionThe combination of SC/B6 and CMT is more effective in treating DSNs than CMT alone. This combination alleviates the adverse effects associated with chemotherapy and improves the QoL of DSN patients, and its application in the clinic is worth promoting.

Clinical observation of the effects of Xihuang pills combined with sodium cantharidinate and vitamin B6 injection in the treatment of tumor-induced fever

Objective To study the effects of Xihuang pills combined with sodium cantharidinate and vitamin B6 injection in the treatment of tumor-induced fever. Methods A total of 100 patients with tumor-induced fever in our hospital from March 2015 to January 2017 were enrolled in this study. The subjects were divided into the control group (n=50) and the treatment group (n=50) randomly. The control group were treated with aspirin-D L-Lysine injection, and the treatment group were treated with Xihuang pills combined with sodium cantharidinate and vitamin B6 injection. The two groups were treated for 2 periods. The clinical effects of the two groups after treatment were compared. The life quality of the two groups after treatment were compared. The serum TNF-α and IL-1β of the two groups before and after treatment were compared. The adverse reaction rates of the two groups during treatment were compared. Results The total efficacy rate of defervescence of the treatment group was 88.0%(44/50) significantly higher than 56.0%(28/50) of the control group (χ2=12.698, P=0.000). After treatment, the daily life score (1.10 ± 0.18 vs. 2.47 ± 0.21, t=35.025), social communication score (1.21 ± 0.13 vs. 2.53 ± 0.25, t=33.124), mental state score (1.08 ± 0.15 vs. 2.75 ± 0.21, t=45.758), appetite score (1.13 ± 0.16 vs. 2.56 ± 0.19, t=40.708), sleep score (1.22 ± 0.17 vs. 2.71 ± 0.20, t=40.139) of the treatment group were significantly lower than those of the control group (P<0.05). After treatment, the serum TNF-α (1.98 ± 0.07 μg/L vs. 2.86 ± 0.13 μg/L, t=42.144), IL-1β (9.20 ± 1.89 μg/L vs. 13.51 ± 2.36 μg/L, t=10.080) of the treatment group were significantly lower than those of the control group (P<0.05). There was no significantly differences of the adverse reaction rates of the two groups during treatment (χ2=0.211, P=0.646). Conclusions The Xihuang pills combined with sodium cantharidinate and vitamin B6 injection for patients with tumor-induced fever has a good efficacy and low incidence of adverse reactions, can improve the quality of life and reduce the serum levels of TNF-α and IL-1β. Key words: Tumor-induced fever; Xihuang pills; Sodium cantharidinate and vitamin B6 injection; Quality of life; Tumor necrosis factor-alpha; Interleukin-1

Effect observation of sodium cantharidate and vitamin B6 combined with concurrent chemoradiotherapy in treatment of locally advanced nasopharyngeal carcinoma

Objective To study the clinical efficacy of sodium cantharidinate and vitamin B6 injection combined with concurrent chemoradiotherapy in treatment of locally advanced nasopharyngeal carcinoma (LA-NPC). Methods 115 patients with LA-NPC in Shanxi Cancer Hospital were randomly assigned to observation group (61 cases) and control group (54 cases) from February 2014 to April 2016. The patients in the observation group were treated with sodium cantharidate and vitamin B6 injection combined with concurrent chemoradiotherapy. The patients in the control group were treated with concurrent chemoradiotherapy. The differences between the two groups were compared in respect of recent curative effect, the quality of life (QOL) and the adverse reactions. Results The recent effective rate was 93.44% (57/61) in the observation group and 79.63% (43/54) in the control group, and there was significant difference between the two groups (χ2= 4.818, P= 0.049). The improvement rate of QOL was 73.77% (45/61) in the observation group and 53.70% (29/54) in the control group, and there was significant difference between the two groups (χ2= 5.028, P= 0.032). The incidence rates of oral cavity mucous membrane inflammation, hematology toxicity, pharynx and esophagus adverse reactions, the gastrointestinal tract adverse reactions and skin fibrosis in the observation group were lower than those in the control group, and there were significant differences between the two groups (all P < 0.05). Conclusion The recent effect of sodium cantharidinate and vitamin B6 injection combined with concurrent chemoradiotherapy on the patients with LA-NPC is obvious. The comprehensive treatment can also reduce adverse reactions and improve the QOL. Key words: Nasopharyngeal neoplasms; Sodium cantharidinate and vitamin B6; Concurrent chemoradiotherapy

Effect of disodium cantharidinate on in vitro lymphocyte immune response in lung cancer patients

Objective To investigate the effect of disodium cantharidinateon in vitro lymphocyte immune response in lung cancer patients.Methods Twenty non-small cell lung cancer patients diagnosed by pathological diagnosis were selected.The effects of different concentrations of disodium cantharidinate and vitamin B6 on lymphocyte proliferation and CD4 + CD25 + T cells,CD25 + FOXP3 + T cells,CD4 + and CD8 + T cells were detected by methyl thiazolyl tetrazolium assay and flow cytometry.Results When the concentrations of disodium cantharidinate and vitamin B6 was less than 10 μg/ml,with the growth of concentration,it stimulated the proliferation of peripheral blood lymphocytes.When the concentration was more than 10 μg/ml,with the growth of concentration,the absorbance value decreased,and the stimulating effect weakened.When the concentration of disodium cantharidinate and vitamin B6 injection was less than 10 μg/ml,with the growth of concentration,CD4 +/CD8 + ratio increased significantly,and CD4 + CD25 +/CD4 + and CD25 + FOXP3 + T cells were significantly lower,which showed statistically significant differences (t =2.171,P =0.032 ; t =2.103,P =0.041 ; t =3.662,P =0.002 ; t =3.201,P =0.003 ; t =3.233,P =0.003).But when the concentration was more than 10 μg/ml,The differences of CD4 +/CD8 + ratio,CD4 + CD25 +/CD4 + and CD25 + FOXP3 + T cells in 10,15,20 μg/ml groups were not statistically significant,which showed that disodium cantharidinate and vitamin B6 injection had a positive effect on enhancing the immune function of lymphocytes in lung cancer in a concentration dependent manner,but high concentration was unhelpful.Conclusion Disodium cantharidinate and vitamin B6 injection can promote lung cancer in vitro lymphocyte proliferation as well as increase its immunity in a certain range. Key words: Lung neoplasms ; Cell culture techniques; Autoimmunity; Disodium cantharidinate

Sodium cantharindinate and vitamin B6 injection in combination with TACE for primary liver cancer

Objective To observe the effect of sodium cantharindinate and vitamin B6 injection combined with TACE for liver cancer complicated with cirrhosis of HBV.Methods 98 patients diagnosed with liver cancer complicated with liver cirrhosis were randomly divided into a sodium cantharindinate and vitamin B6 treatment group and a control group.The treatment group were treated with 50 ml disodium cantharindinate and vitamin B6 injection and 250-500 ml normal saline on day 1-10 once per day by intravenous drip and received TACE treatment after intravenous infusion day 2 for 10 days as a treatment course.2 treatment courses were a treatment period.Besides disodium cantharindinate and vitamin B6 injection,the control group administrated some other drug protecting liver and improving immunity and received transcatheter interventional chemotherapy and embolization.The short-term efficacies,toxicity,liver function,and indexes of hepatic fibrosis were evaluated after two treatment courses.Results After two treatment courses,there were statistical differences in efficacy,toxicity,liver function and indexes of hepatic fibrosis between the 2 groups.Conclusions Sodium cantharindinate and vitamin B6 injection combined with TACE for liver cancer complicated with cirrhosis of HBV is effective and safe. Key words: Sodium cantharindinate and vitamin B6; Primary liver cancer

Adjuvant treatment with disodium cantharidinate and vitamin B6 injection for patients with hepatocellular carcinoma: a Meta analysis based on randomized controlled trials

Objective To evaluate the effectiveness and safety of disodium cantharidinate and vitamin B6 injection in the adjuvant treatment for patients with hepatocellular carcinoma (HCC).Methods The pertinent literature of adjuvant treatment with disodium cantharidinate and vitamin B6 injection for patients with HCC were searched in Embase,PubMed,Cochrane Library,Chinese Biomedicine Literature Database,VIP Database,China National Knowledge Infrastructure Database (CNKI) and Wanfang Database.Meta analysis was carried out using Review Manager (version5.0) provided by Cochrane Collaboration.Results Four randomized controlled trials totaling 307 patients were included.Results showed that compared to control group,the adjuvant treatment with disodium cantharidinate and vitamin B6 injection significantly enhanced the short-term effect [RR =1.40,95％ CI (1.04,1.89),P =0.03] and improved the quality of life [RR =1.67,95％ CI (1.28,2.17),P =0.000 1].Moreover,the combination of disodium cantharidinate and vitamin B6 injection alleviated gastrointestinal reaction [RR =0.62,95％ CI (0.42,0.93),P =0.02],bone marrow depression [RR =0.47,95 ％ CI (0.31,0.71),P =0.000 3] and injury of liver function [RR =0.63,95 ％ CI (0.42,0.93),P =0.02].Conclusion Disodium cantharidinate and vitamin B6 injection can enhance the effectiveness,improve the quality of life and decrease the adverse effect rate in patients with intermediate or advanced HCC,and it is worth popularizing and applying. Key words: Liver neoplasms; Neoadjuvant therapy; Randomized controlled trial ; Meta-analysis; Disodium cantharidinate and vitamin B6 injection

Clinical observation of sodium cantharidate vitamin B6 injection combined with chemotherapy for acute leukemia patients

Objective To observe the efficacy of sodium cantharidate vitamin B6 injection combined with chemotherapy for acute leukemia patients.Methods All 113 acute leukemia patients were divided into therapeutic group (81 cases) and control group (32 cases) by whether to inject sodium cantharidate vitamin B6 injection or not.The two groups chose the standard chemotherapy,therapeutic group added sodium cantharidate vitamin B6 injection while the control group not.The remission,suppression situation of bone marrow after chemotherapy,time of marrow restoration and other toxic effects were observed.Results In the therapeutic group,there were 39 (48.15％) cases of complete remission (CR),31 (38.27％) cases of partial remission (PR),11 (13.58％) cases of no remission (NR).In the control group,there were 10 (31.25％) cases of CR,10 (31.25％) cases of PR and 12 (37.50％) cases of NR,the remission rate in the therapeutic group was higher than the control group,there was significant difference between the two groups (x2 =8.270,P =0.016).The remission rates of middle-aged and elderly patients in therapeutic group were higher than that in control group (x2 =6.360,P =0.042 ; x2 =6.432,P =0.040),but there was no difference between young patients of therapeutic group and control group (x2 =1.829,P =0.401).The remission rate of acute myeloid leukemia patients in therapeutic group was higher than that control group (x2 =11.411,P =0.003),but there was no difference between acute lymphocytic leukemia patients of therapeutic group and control group (x2 =1.739,P =0.419).The inhibition of granulocytic and thrombocyte was better than that in control group (Z =-2.142,P =0.032 ; Z =-2.490,P =0.013),while no difference in hemoglobin between the two groups (Z =-0.483,P =0.629).The time of marrow restoration in therapeutic group [(6.26 ± 1.34) days] wasshorter than that in control group [(11.33±2.18) days](t =-14.186,P=0.000).Conclusion Sodium cantharidate vitamin B6 injection combined with chemotherapy can improve the efficacy of acute leukemia in elderly patients,also relieve the suppression of bone marrow after chemotherapy. Key words: Cantharidin; Leukemia, biphenotypic, acute ; Drug therapy

Nested case control study to analyze suspected cases and their related factors of allargic reactions to parenterally administered Dengzhan Xixin

To assess if adverse drug reactions (ADR)s to parenterally administered Dengzhan Xixin are allergic in origin. Hospital information system (HIS) data from 20 hospitals in China were used to carry out a nested case control design study. Included were patients who received dexamethasone for suspected allergic reactions after receiving parenterally administered Dengzhan Xixin. These were compared with non-allergic reaction people. Single factor logistic regression and multiple factor logistic regression were used to analyze data. Condition on admission, allergic history, dosage, disease status and drug combinations were taken into account in cases of suspected allergic reactions. After analysis we found that the condition on admission had a significant effect, P = 0.008 3, OR value = 5.642 on suspected cases of allergic reactions. Using vitamin B6 injection or ambroxol at the same time as parenterally administered Dengzhan Xixin were significant, P = 0.000 2 and 0.016 7, OR value = 9.545 and 3.194, risk factors in this group. Based on this current research, condition on admission as well as the concomitant use of vitamin B6 or ambroxol may be the risk factors in suspected cases of allergic reactions. However, further research for verification is required. This study can provide guidance for safe clinical practice in using parenterally administered. It can also provide a new method for the pharmcovigilance of parenterally administered Dengzhan Xixin.

Disodium Cantharidinate and Vitamin B6 Injection in combination with radiotherapy induces apoptosis and inhibits proliferation in hepatocellular carcinoma cell line HepG2

Disodium Cantharidinate and Vitamin B6 Injection in combination with radiotherapy induces apoptosis and inhibits proliferation in hepatocellular carcinoma cell line HepG2

Amino acid metabolism in the brain with convulsive disorders Part 2: The effects of anticonvulsants on convulsions and free amino acid patterns in the brain of El mouse

To elucidate the changes of free amino acid patterns in brains of El mice induced by several anticonvulsants, the free amino acid levels in brains were measured by an amino acid autoanalyzer 24 hours after intraperitoneal injection of PB, PHT or vitamin B6 or subcutaneous injection of ACTH. Compared to the preconvulsion group, the total free amino acid level increased in the ACTH group clearly. In the PB group, the levels of threonine, glutamine, lysine, histidine and homocarnosine increased and that of ornithine decreased; in the PHT group, an increase of glutamine and histidine and a decrease of beta-alanine and ornithine were observed; in the ACTH group, an increase of aspartic acid, threonine, serine, glutamic acid, glutamine, alanine and GABA and a decrease of cystathionine and ornithine were also observed; and in the vitamin B6 group, an increase of taurine and a decrease of cystathionine were recognized. These facts suggest that the sedative activity of these drugs except ACTH might be partially explained by the increase of inhibitory amino acids in the brain, such as glutamine, homocarnosine and taurine, and that of ACTH by the dehydration of the brain, resulting in concentration of many free amino acids.